1. Almost 50 non-oncology drugs found to kill cancer cells —Chi-Med stops pancreatic cancer trial upon early success — GSK gets speedy review for one of its top drug prospects— See more on our front page news TRY TWO WEEKS OF OUR EMAIL NEWS HEADLINES FOR FREE
    Dismiss Notice
  2. Think you have witnessed fraud?Ask a Whistleblower Attorney -- a chance to discuss whistleblower-related legal issues with practicing whistleblower attorneys.
    Dismiss Notice

Hologic quarterly results

Discussion in 'Minerva Surgical' started by anonymous, Aug 9, 2019 at 12:09 PM.

  1. anonymous

    anonymous Guest

    Hologic has increased sales their last 2 quarters. What are they doing to do that? Is the party over here at Minerva? Seems like we would be taking share still - since there is so much out there.

    Thoughts?
     
  2. anonymous

    anonymous Guest

     
  3. anonymous

    anonymous Guest

    Hello! Here are the facts. Novasure sales have been down 10 quarters in a row, when compared to the same quarter of the previous year. That’s how we compare quarterly sales on Wall Street. Actual Q2 Novasure sales over the past 4 years as reported by Hologic in their SEC 10Q filings have declined as follows: Q2 2016-$61M, Q2 2017-$57.5M, Q2 2018-$53.5M, and Q2 2019-$48.3M